Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3848023 | American Journal of Kidney Diseases | 2014 | 7 Pages |
Abstract
Despite increases in precision of the treatment effect, eGFR declines less than a doubling of serum creatinine value did not consistently improve statistical power of the clinical trials due to attenuation of the treatment effect. Attenuation of the treatment effect appears to be due in part to acute effects of ARBs on eGFR. These findings should be taken into account when using lesser eGFR declines as alternative end points for clinical trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Hiddo J. PhD, Misghina MSc, Lesley A. MD, MS, Ron MD, PhD, Hans-Henrik MD, PhD, Jamie P. MD, Hasi MSc, Josef MD, PhD, Tom PhD, Andrew S. MD, Dick MD, PhD,